China Sxt Pharmaceuticals
(NASDAQ) SXTC
China Sxt Pharmaceuticals Financials at a Glance
Market Cap
$85.23M
Revenue (TTM)
$1.74M
Net Income (TTM)
-$3.30M
EPS (TTM)
-$35.49
P/E Ratio
-0.06
Dividend
$0.00
Beta (Volatility)
1.93 (High)
Dividend
$0.00
Beta (Volatility)
1.93 (High)
Price
$2.20
Volume
47,012.83
Open
$2.44
Price
$2.20
Volume
47,012.83
Open
$2.44
Previous Close
$2.23
Daily Range
$2.18 - $2.44
52-Week Range
$1.25 - $1,046.99
Estimated Earnings Date
Jul 17, 2023
Dividend
$0.00
Beta (Volatility)
1.93 (High)
Price
$2.20
Volume
47,012.83
Open
$2.44
Previous Close
$2.23
Daily Range
$2.18 - $2.44
52-Week Range
$1.25 - $1,046.99
Estimated Earnings Date
Jul 17, 2023
SXTC News
Motley Fool Moneyball Superscore
Our CEO Is Handing Members His Secret Weapon
It's called Motley Fool Moneyball, our new proprietary AI tool
We spent over half a million dollars in R&D to build a tool that makes stock research faster, sharper, and smarter. Our analysts use it every day, and now, you can too.
Get Access NowAbout China Sxt Pharmaceuticals
Industry
Pharmaceuticals
Sector
Health CareEmployees
75
CEO
Sze Beng Lim; Feng Zhou
Website
www.sxtchina.comHeadquarters
Taizhou, 225300, CN
SXTC Financials
Key Financial Metrics (TTM)
Gross Margin
26%
Operating Margin
-2%
Net Income Margin
-3%
Return on Equity
-50%
Return on Capital
-10%
Return on Assets
-9%
Earnings Yield
-16.67%
Dividend Yield
0.00%
Payout Ratio
0.00%
Stock Overview
Market Cap
$85.23M
Shares Outstanding
38.22M
Volume
47.01K
Avg. Volume
83.35K
Financials (TTM)
Gross Profit
$367.43K
Operating Income
-$2.68M
EBITDA
-$2.57M
Operating Cash Flow
-$2.35M
Capital Expenditure
-$2.02K
Free Cash Flow
-$2.35M
Cash & ST Invst.
$18.10M
Total Debt
$983.88K
China Sxt Pharmaceuticals Performance Analysis
Revenue Growth Rate
Annual and quarterly growth comparisonEarnings Per Share Growth Rate
Annual and quarterly EPS growth comparisonQuarterly Performance
Revenue
$455.71K
-7.8%
Gross Profit
$116.34K
-12.4%
Gross Margin
25.53%
N/A
Market Cap
$85.23M
N/A
Market Cap/Employee
$1.14M
N/A
Employees
75
N/A
Net Income
-$1.25M
-137.9%
EBITDA
-$1.01M
-127.6%
Quarterly Fundamentals
Total Cash
$21.17M
+14.3%
Total Debt
$1.20M
-87.8%
Accounts Receivable
$2.87M
+72.2%
Inventory
$751.35K
-52.7%
Long Term Debt
$158.26K
-46.9%
Short Term Debt
$1.04M
-89.1%
Return on Assets
-9.49%
N/A
Return on Invested Capital
-10.01%
N/A
Free Cash Flow
-$495.09K
+27.0%
Operating Cash Flow
-$494.08K
+26.7%